DUBLIN, May 16, 2019 /PRNewswire/ -- Allergan plc (NYSE:
AGN) today announced that Chairman and CEO Brent Saunders will participate in a fireside
chat at the Bernstein 35th Annual Strategic Decisions
Conference in New York, NY. The
presentation will begin at 9:00 a.m. Eastern
Time on Thursday, May 30, 2019.
The presentation will be webcast live and can be accessed on
Allergan's Investor Relations website at
https://www.allergan.com/investors/events-presentations. The
webcast can also be accessed through the following URL:
https://event.webcasts.com/starthere.jsp?ei=1244856&tp_key=4e5c44cd1d&tp_special=8
An archived version will be available within approximately one
hour of the live presentation and can be accessed at the same
location for 180 days.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical
leader focused on developing, manufacturing and commercializing
branded pharmaceutical, device, biologic, surgical and regenerative
medicine products for patients around the world. Allergan markets a
portfolio of leading brands and best-in-class products primarily
focused on four key therapeutic areas including medical aesthetics,
eye care, central nervous system and gastroenterology. As part of
its approach to delivering innovation for better patient care,
Allergan has built one of the broadest pharmaceutical and device
research and development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
CONTACTS:
Allergan:
Investors:
Manisha
Narasimhan, PhD
(862) 261-7162
Media:
Amy Rose
(862) 289-3072
Lisa Brown
(862) 261-7320
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-to-present-at-the-bernstein-strategic-decisions-conference-300851114.html
SOURCE Allergan plc